Stabilis

Dexamethasone sodium phosphate



Εμπορική ονομασία

Aacidexam	Βέλγιο, Λουξεμβούργο
Alin	Μεξικό
Aquason	Ιράν
Bexine	Μεξικό
Decadron	Αργεντινή, Βενεζουέλα, Βραζιλία, Εκουαδόρ, Ελλάδα, Η.Π.Α., Ιταλία, Κολομβία, Μεξικό, Ολλανδία
Dexabene	Αυστρία, Γερμανία
Dexaven	Πολωνία
Fortecortin	Αίγυπτος, Αυστρία, Γερμανία, Ελβετία, Ισπανία, Λουξεμβούργο
Onadron	Τουρκία
Oradexon	Ελλάδα, Κολομβία, Μαρόκο, Ολλανδία, Πορτογαλία, Σαουδική Αραβία, Φινλανδία
Soldesanil	Ελλάδα

Σταθερότητα διαλυμάτων

	10 mg/ml	23°C		91				28
	10 mg/ml	4°C		91				28
PVC	0,08 mg/ml	2-8°C	?	14				4602
PVC	0,08 mg/ml	20-23°C	?	14				4602
PVC	0,4 mg/ml	2-8°C	?	14				4602
PVC	0,4 mg/ml	20-23°C	?	14				4602
PVC	0,08 mg/ml	2-8°C	?	14				4602
PVC	0,08 mg/ml	20-23°C	?	14				4602
PVC	0,4 mg/ml	2-8°C	?	14				4602
PVC	0,4 mg/ml	20-23°C	?	14				4602
PP	0,1 & 1 mg/ml	25°C	?	22				1701
PP	10 mg/ml	23°C		55				28

		10 mg/ml	4°C		55			28
?		1 >> 4 mg/ml	22°C		28			546
?		1 >> 4 mg/ml	4°C		28			546

Σταθερότητα σε μίγματα

		0,12 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4	57
		4 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
		0,05 & 0,1 & 0,2 mg/ml	25°C		Azasetron : 0,1 mg/ml	48	4301
		0,34 mg/ml	25°C		Ondansetron hydrochloride : 0,14 & 0,45 mg/ml	24	25
		0,05 & 0,1 & 0,2 mg/ml	4°C		Azasetron : 0,1 mg/ml	14	4301
		4 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
		0,28 mg/ml	25°C		Lorazepam : 0,028 mg/ml Ondansetron hydrochloride : 0,44 mg/ml	24	25
		0,34 mg/ml	25°C		Ondansetron hydrochloride : 0,14 & 0,45 mg/ml	24	25
	RL	4 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
	0.45	4 mg/ml	23°C		Cefpirome sulfate : 50 mg/ml	8	280
	Ø	0,178 mg/ml	2-8°C		Rolapitant : 1,6 mg/ml Palonosetron hydrochloride : 2,1 µg/ml	48	4062
	Ø	0,093 mg/ml	2-8°C		Rolapitant : 1,6 mg/ml Palonosetron hydrochloride : 2,1 µg/ml	48	4062
	Ø	0,086 mg/ml	20-25°C		Rolapitant : 1,7 mg/ml	6	3927
	Ø	0,170 mg/ml	20-25°C		Rolapitant : 1,7 mg/ml	6	3927
	Ø	0,093 mg/ml	20-25°C		Rolapitant : 1,6 mg/ml Palonosetron hydrochloride : 2,1 µg/ml	24	4062
	Ø	0,178 mg/ml	20-25°C		Rolapitant : 1,6 mg/ml Palonosetron hydrochloride : 2,1 µg/ml	24	4062
PVC		0,43 mg/ml	15-25°C		Ondansetron hydrochloride : 0,15 mg/ml	28	23
PVC		0,02 & 0,4 mg/ml	2-6°C		Ondansetron hydrochloride : 0,1 >> 0,4 mg/ml	30	30
PVC		0,2 & 0,4 mg/ml	2-6°C		Ondansetron hydrochloride : 0,1 >> 0,64 mg/ml	30	30
PVC		0,43 mg/ml	2-8°C		Ondansetron hydrochloride : 0,15 mg/ml	28	23
PVC		0,074 >> 0.345 mg/ml	22°C		Granisetron hydrochloride : 0,056 mg/ml	3	29
PVC		0.2 & 0.4 mg/ml	22°C-23°C		Ondansetron hydrochloride : 0,1 >> 0,4 mg/ml	48	30
PVC		0,2 & 0,4 mg/ml	22°C-23°C		Ondansetron hydrochloride : 0,1 >> 0,64 mg/ml	48	30
PVC		0,08 & 0,20 mg/ml	23°C	?	Granisetron hydrochloride : 0,02 & 0,06 mg/ml	35	1633

PVC		0,080 - 0,600 mg/ml	23°C-25°C		Granisetron hydrochloride : 0,010 - 0,040 mg/ml	14	27
PVC		0,28 mg/ml	25°C		Ondansetron hydrochloride : 0,14 & 0,45 mg/ml	24	25
PVC		0,2 & 0,4 mg/ml	25°C		Palonosetron hydrochloride : 5 µg/ml	48	1932
PVC		0,08 - 0,60 mg/ml	4°C		Granisetron hydrochloride : 0,01 - 0,04 mg/ml	14	27
PVC		0,2 & 0,4 mg/ml	4°C		Palonosetron hydrochloride : 5 µg/ml	14	1932
PVC		0,08 & 0,20 mg/ml	4°C		Granisetron hydrochloride : 0,02 & 0,06 mg/ml	35	1633
PVC		0,43 mg/ml	15-25°C		Ondansetron hydrochloride : 0,15 mg/ml	28	23
PVC		0,43 mg/ml	2-8°C		Ondansetron hydrochloride : 0,15 mg/ml	28	23
PVC		0.074 >> 0.345 mg/ml	22°C		Granisetron hydrochloride : 0,056 mg/ml	3	29
PVC		0,08 & 0,20 mg/ml	23°C	?	Granisetron hydrochloride : 0,02 & 0,06 mg/ml	35	1633
PVC		0,080 - 0,600 mg/ml	23°C-25°C		Granisetron hydrochloride : 0,010 - 0,040 mg/ml	14	27
PVC		0,28 mg/ml	25°C		Ondansetron hydrochloride : 0,14 & 0,45 mg/ml	24	25
PVC		0,2 & 0,4 mg/ml	25°C		Palonosetron hydrochloride : 5 µg/ml	48	1932
PVC		0,08 - 0,60 mg/ml	4°C		Granisetron hydrochloride : 0,01 - 0,04 mg/ml	14	27
PVC		0,2 & 0,4 mg/ml	4°C		Palonosetron hydrochloride : 5 µg/ml	14	1932
PVC		0,08 & 0,20 mg/ml	4°C		Granisetron hydrochloride : 0,02 & 0,06 mg/ml	35	1633
PE		0,09 mg/ml	- 20°C		Ondansetron hydrochloride : 0,09 mg/ml	90	3174
PE		0,09 mg/ml	2-8°C	?	Ondansetron hydrochloride : 0,09 mg/ml	90	3174
PP		0,07 mg/ml	23°C		Ketamine hydrochloride : 3,6 & 42,8 mg/ml	8	2022
PP		0.33>>3.33 mg/ml	25°C		Tramadol hydrochloride : 8.33>>33.33 mg/ml	5	2211
PP		0.33>>3.33 mg/ml	25°C		Furosemide : 3.33>>10 mg/ml	5	2205
PP		0.27 mg/ml	25°C		Lorazepam : 0.16 mg/ml Diphenhydramine hydrochloride : 4 mg/ml	48	2132
PP		0,33 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	48	1932
PP		0,07 mg/ml	37°C		Ketamine hydrochloride : 3,6 & 42,8 mg/ml	8	2022
PP		0,33 mg/ml	4°C		Palonosetron hydrochloride : 25 µg/ml	14	1932
PP		0,07 mg/ml	4°C		Ketamine hydrochloride : 3,6 & 42,8 mg/ml	8	2022
PP		0.33>>3.33 mg/ml	5°C		Furosemide : 3.33>>10 mg/ml	5	2205
PP		0,33 mg/ml	25°C		Palonosetron hydrochloride : 25 µg/ml	48	1932
PP		0,33 mg/ml	4°C		Palonosetron hydrochloride : 25 µg/ml	14	1932
POF		0.1 mg/ml	2-8°C	?	Alizapride hydrochloride : 1 mg/ml	30	3925
POF		0.1 mg/ml	2-8°C	?	Ondansetron hydrochloride : 0.08 mg/ml	30	3925
POF		0,2 mg/ml	23-27°C		Tropisetron hydrochloride : 0,05 mg/ml	48	3981
POF		0,1 mg/ml	23-27°C		Tropisetron hydrochloride : 0,05 mg/ml	48	3981

POF	▲	0,1 mg/ml	23-27°C		Dolasetron mesylate : 1 mg/ml	48	3981
POF	▲	0,2 mg/ml	23-27°C		Dolasetron mesylate : 1 mg/ml	48	3981
POF	▲	0,1 mg/ml	23-27°C		Azasetron : 0,2 mg/ml	48	3981
POF	▲	0,2 mg/ml	23-27°C		Azasetron : 0,2 mg/ml	48	3981
POF	▲	0,1 mg/ml	23-27°C		Ondansetron hydrochloride : 0,08 mg/ml	48	3981
POF	▲	0,2 mg/ml	23-27°C		Ondansetron hydrochloride : 0,08 mg/ml	48	3981
POF	▲	0,2 mg/ml	23-27°C		Palonosetron hydrochloride : 2.5 µg/ml	48	3981
POF	▲	0,1 mg/ml	23-27°C		Palonosetron hydrochloride : 2.5 µg/ml	48	3981
POF	▲	0,1 mg/ml	23-27°C		Ramosetron hydrochloride : 3 µg/ml	48	3981
POF	▲	0.2 mg/ml	23-27°C		Ramosetron hydrochloride : 3 µg/ml	48	3981
POF	▲	0,05 & 0,1 & 0,2 mg/ml	25°C		Azasetron : 0,1 mg/ml	48	4301
POF	▲	0,05 & 0,1 & 0,2 mg/ml	4°C		Azasetron : 0,1 mg/ml	14	4301
POF	◆	0,1 mg/ml	23-27°C		Ondansetron hydrochloride : 0,08 mg/ml	48	3981
POF	◆	0,2 mg/ml	23-27°C		Ondansetron hydrochloride : 0,08 mg/ml	48	3981
POF	◆	0,2 mg/ml	23-27°C		Palonosetron hydrochloride : 2.5 µg/ml	48	3981
POF	◆	0,1 mg/ml	23-27°C		Palonosetron hydrochloride : 2.5 µg/ml	48	3981
POF	◆	0,1 mg/ml	23-27°C		Ramosetron hydrochloride : 3 µg/ml	48	3981
POF	◆	0.2 mg/ml	23-27°C		Ramosetron hydrochloride : 3 µg/ml	48	3981
PP	▲	0,2 & 1 mg/ml	22°C		Granisetron hydrochloride : 0,150 mg/ml	3	29
PP	◆	0,2 & 1 mg/ml	22°C		Granisetron hydrochloride : 0,150 mg/ml	3	29
CZ®	∅	0,170 mg/ml	20-25°C		Rolapitant : 1,7 mg/ml	6	3927
CZ®	∅	0,086 mg/ml	20-25°C		Rolapitant : 1,7 mg/ml	6	3927
?	▲	0,16 mg/ml	25°C		Metoclopramide hydrochloride : 1,6 mg/ml Diphenhydramine hydrochloride : 2 mg/ml	48	3779

Συμβατότητες

	✓	Dexamethasone sodium phosphate : 4 mg/ml Aciclovir sodium : 5 mg/ml	▲	2335
	✓	Dexamethasone sodium phosphate : 0.2 mg/ml Aciclovir sodium : 5 mg/ml	◆	336
	✓	Dexamethasone sodium phosphate : 0.1 mg/ml Alizapride hydrochloride : 1 mg/ml	▲	3925
	✓	Dexamethasone sodium phosphate : 1 mg/ml Allopurinol sodium : 3 mg/ml	▲	307

		Dexamethasone sodium phosphate : 1 mg/ml Amifostine : 10 mg/ml		3
		Dexamethasone sodium phosphate : 4 mg/ml Amikacin sulfate : 50 mg/ml	0.45	132
		Dexamethasone sodium phosphate : 0,03 mg/ml Aminophylline : 0,625 mg/ml		1259
		Dexamethasone sodium phosphate : 4 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Dexamethasone sodium phosphate Amoxicillin sodium / clavulanic acid		3545
		Dexamethasone sodium phosphate : 2 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Dexamethasone sodium phosphate : 1 mg/ml Amsacrine : 1 mg/ml		253
		Dexamethasone sodium phosphate : 1 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml Azasetron : 0.2 mg/ml		3981
		Dexamethasone sodium phosphate : 0.05 >> 0.2 mg/ml Azasetron : 0.1 mg/ml		4301
		Dexamethasone sodium phosphate : 1 mg/ml Aztreonam : 40 mg/ml		99
		Dexamethasone sodium phosphate : 1 mg/ml Bivalirudin : 5 mg/ml		1713
		Dexamethasone sodium phosphate Bleomycin sulfate		3646
		Dexamethasone sodium phosphate Bleomycin sulfate		4154
		Dexamethasone sodium phosphate : 0.19 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml		3976
		Dexamethasone sodium phosphate : 4 mg/ml Caffeine : 10 mg/ml	∅	3964
		Dexamethasone sodium phosphate Calcium gluconate		4964
		Dexamethasone sodium phosphate Calcium gluconate		3644
		Dexamethasone sodium phosphate : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Dexamethasone sodium phosphate : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Dexamethasone sodium phosphate : 4 mg/ml Cefpirome sulfate : 50 mg/ml	0.45	280
		Dexamethasone sodium phosphate : 4 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Dexamethasone sodium phosphate : 4 mg/ml Cefpirome sulfate : 50 mg/ml	RL	280
		Dexamethasone sodium phosphate : 4 mg/ml Cefpirome sulfate : 50 mg/ml		280
		Dexamethasone sodium phosphate : 1 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Dexamethasone sodium phosphate : 1 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249

		Dexamethasone sodium phosphate : 1 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Dexamethasone sodium phosphate : 1 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Dexamethasone sodium phosphate : 1 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Dexamethasone sodium phosphate : 1 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Dexamethasone sodium phosphate : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Dexamethasone sodium phosphate : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Dexamethasone sodium phosphate : 0.04 mg/ml Cimetidine hydrochloride : 3 mg/ml		1201
		Dexamethasone sodium phosphate : 4 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Dexamethasone sodium phosphate : 4 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Dexamethasone sodium phosphate : 1 mg/ml Cladribine : 0.015 mg/ml		1496
		Dexamethasone sodium phosphate : 1 mg/ml Cladribine : 0.5 mg/ml		1496
		Dexamethasone sodium phosphate : 4 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Dexamethasone sodium phosphate Daunorubicin hydrochloride		3668
		Dexamethasone sodium phosphate Daunorubicin hydrochloride		3604
		Dexamethasone sodium phosphate Daunorubicin hydrochloride liposome		3577
		Dexamethasone sodium phosphate : 1 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Dexamethasone sodium phosphate Diamorphine hydrochloride		4982
		Dexamethasone sodium phosphate Dimenhydrinate		2087
		Dexamethasone sodium phosphate : 2 >> 10 mg/ml Diphenhydramine hydrochloride : 5 >> 35 mg/ml		389
		Dexamethasone sodium phosphate : 2 mg/ml Diphenhydramine hydrochloride : 40 mg/ml		389
		Dexamethasone sodium phosphate : 4 >> 10 mg/ml Diphenhydramine hydrochloride : < 5 mg/ml		389
		Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml Dolasetron mesylate : 1 mg/ml		3981
		Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml Dolasetron mesylate : 0.05 mg/ml		3981
		Dexamethasone sodium phosphate : 1 mg/ml Doripenem : 5 mg/ml		2262
		Dexamethasone sodium phosphate : 1 mg/ml Doripenem : 5 mg/ml		2262
		Dexamethasone sodium phosphate Doxapram hydrochloride		3668

		Dexamethasone sodium phosphate Doxorubicin hydrochloride		3668
		Dexamethasone sodium phosphate : 1 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Dexamethasone sodium phosphate : 1 mg/ml Famotidine : 2 mg/ml		215
		Dexamethasone sodium phosphate : 10 mg/ml Famotidine		397
		Dexamethasone sodium phosphate : 1 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Dexamethasone sodium phosphate : 4 mg/ml Fentanyl citrate : 50 µg/ml		63
		Dexamethasone sodium phosphate : 1 mg/ml Fentanyl citrate : 25 µg/ml		1974
		Dexamethasone sodium phosphate : 1 mg/ml Filgrastim : 30 µg/ml		244
		Dexamethasone sodium phosphate : 4 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Dexamethasone sodium phosphate : 4 mg/ml Fluconazole : 2 mg/ml		496
		Dexamethasone sodium phosphate : 1 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Dexamethasone sodium phosphate : 0,1 mg/ml Fosaprepitant dimeglumine : 1 mg/ml		3459
		Dexamethasone sodium phosphate : 10 mg/ml Foscarnet sodium : 24 mg/ml	∅	73
		Dexamethasone sodium phosphate : 1 mg/ml Fosfomycin : 30 mg/ml		4055
		Dexamethasone sodium phosphate : 1 mg/ml Fosfomycin : 30 mg/ml		4055
		Dexamethasone sodium phosphate : 4 mg/ml Furosemide : 1 mg/ml		1232
		Dexamethasone sodium phosphate : 0.33>>3.33 mg/ml Furosemide : 3.33>>10 mg/ml		2205
		Dexamethasone sodium phosphate : 4 mg/ml Gallium nitrate : 1 mg/ml		91
		Dexamethasone sodium phosphate : 1 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Dexamethasone sodium phosphate Glycopyrronium bromide		3668
		Dexamethasone sodium phosphate : 0.050 >> 0.350 mg/ml Granisetron hydrochloride : 0.008 >> 0.053 mg/ml		1633
		Dexamethasone sodium phosphate : 0.074 >> 1 mg/ml Granisetron hydrochloride : 0.056 & 0.15 mg/ml		29
		Dexamethasone sodium phosphate : 0.08 & 0.6 mg/ml Granisetron hydrochloride : 0.01 & 0.04 mg/ml		27
		Dexamethasone sodium phosphate : 0.24 mg/ml Granisetron hydrochloride : 0.02 mg/ml		57
		Dexamethasone sodium phosphate : 0,08 mg/ml		4776
		Dexamethasone sodium phosphate : 0.08 & 0.6 mg/ml Granisetron hydrochloride : 0.01 & 0.04 mg/ml		27

		Dexamethasone sodium phosphate : 0.074 >> 1 mg/ml Granisetron hydrochloride : 0.056 & 0.15 mg/ml		29
		Dexamethasone sodium phosphate : 0.050 >> 0.350 mg/ml Granisetron hydrochloride : 0.008 >> 0.053 mg/ml		1633
		Dexamethasone sodium phosphate : 0.24 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Dexamethasone sodium phosphate : 0,2 >>0,4 mg/ml Haloperidol lactate : 0,25 >> 0,5 mg/ml		4404
		Dexamethasone sodium phosphate : 0,2 >>0,4 mg/ml Haloperidol lactate : 0,25 >> 0,5 mg/ml		4404
		Dexamethasone sodium phosphate : 0,44 & 1,33 mg/ml Haloperidol lactate : 0,21 & 0,62 mg/ml		1971
		Dexamethasone sodium phosphate : 1 mg/ml		301
		Dexamethasone sodium phosphate : 4 mg/ml		316
		Dexamethasone sodium phosphate : 0.08 mg/ml Heparin sodium : 50 UI/ml		317
		Dexamethasone sodium phosphate : 1 mg/ml Hetastarch : 60 mg/ml		1721
		Dexamethasone sodium phosphate Hyaluronidase		3184
		Dexamethasone sodium phosphate : 1 mg/ml		1415
		Dexamethasone sodium phosphate : 0.5 mg/ml		3967
		Dexamethasone sodium phosphate : 4 mg/ml	RL	4603
		Dexamethasone sodium phosphate		3668
		Dexamethasone sodium phosphate : 1 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		1974
		Dexamethasone sodium phosphate : > 3 mg/ml Hydromorphone hydrochloride : > 15 mg/ml		389
		Dexamethasone sodium phosphate Hydromorphone hydrochloride		5073
		Dexamethasone sodium phosphate : 2 >> 10 mg/ml Hydromorphone hydrochloride : < 10 mg/ml		389
		Dexamethasone sodium phosphate : < 2 mg/ml Hydromorphone hydrochloride : 1 >> 40 mg/ml		389
		Dexamethasone sodium phosphate : 10 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Dexamethasone sodium phosphate : 0.2 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
△pH >±1		Dexamethasone sodium phosphate : 1 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
△pH >±1		Dexamethasone sodium phosphate : 1 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Dexamethasone sodium phosphate : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Dexamethasone sodium phosphate : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Dexamethasone sodium phosphate : 10 mg/ml Ketamine hydrochloride : 50 mg/ml		2109

		Dexamethasone sodium phosphate : 0.07 mg/ml Ketamine hydrochloride : 3.57 & 42.85 mg/ml		2022
		Dexamethasone sodium phosphate : 4 mg/ml Ketamine hydrochloride : 50 mg/ml		4389
		Dexamethasone sodium phosphate : 4 mg/ml Levofloxacine : 5 mg/ml		1072
		Dexamethasone sodium phosphate : 0,2 >> 0,4 mg/ml Levomepromazine : 0,625 >>2,5 mg/ml		4404
		Dexamethasone sodium phosphate : 0,2 >> 0,4 mg/ml Levomepromazine : 0,625 >>2,5 mg/ml		4404
		Dexamethasone sodium phosphate : 1 mg/ml Linezolid : 2 mg/ml		1925
		Dexamethasone sodium phosphate : 4 mg/ml Lorazepam : 0.33 mg/ml		186
		Dexamethasone sodium phosphate Magnesium sulfate		3838
		Dexamethasone sodium phosphate : 1 mg/ml Melphalan : 0.1 mg/ml		169
		Dexamethasone sodium phosphate : 10 mg/ml Meropenem : 1 & 50 mg/ml		266
		Dexamethasone sodium phosphate : 4 mg/ml Meropenem : 50 mg/ml		4319
		Dexamethasone sodium phosphate : 4 mg/ml Meropenem : 1 & 20 mg/ml		266
		Dexamethasone sodium phosphate Metaraminol		5046
		Dexamethasone sodium phosphate : 1 mg/ml Methadone hydrochloride : 1 mg/ml		1974
		Dexamethasone sodium phosphate : 4 mg/ml Methotrexate sodium : 30 mg/ml		150
		Dexamethasone sodium phosphate : 0.44 & 1.33 mg/ml Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml		1971
		Dexamethasone sodium phosphate : 0,44 & 1,33 mg/ml Midazolam hydrochloride : 0,5 & 1,5 mg/ml		1971
		Dexamethasone sodium phosphate : 0,2 >>0,4 mg/ml Midazolam hydrochloride : 1,2 mg/ml		4404
		Dexamethasone sodium phosphate : 0.5 mg/ml Midazolam hydrochloride : 0.625 mg/ml		1901
		Dexamethasone sodium phosphate : 0,2 >>0,4 mg/ml Midazolam hydrochloride : 1,2 mg/ml		4404
		Dexamethasone sodium phosphate : 0,25 mg/ml Midazolam hydrochloride : 0,25 mg/ml		1637
		Dexamethasone sodium phosphate : 4 mg/ml Midazolam hydrochloride : 5 mg/ml		186
		Dexamethasone sodium phosphate : 4 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Dexamethasone sodium phosphate : > 0,25 mg/ml Midazolam hydrochloride : > 0,25 mg/ml		1637
		Dexamethasone sodium phosphate : 0.5 >> 20 mg/ml Morphine hydrochloride : 1 >> 50 mg/ml		1866
		Dexamethasone sodium phosphate : 0.44 & 1.33 mg/ml Morphine hydrochloride : 1.68 & 5 mg/ml		1971

		Dexamethasone sodium phosphate : 0.2 mg/ml Morphine sulfate : 1 mg/ml		62
		Dexamethasone sodium phosphate : 1 mg/ml Morphine sulfate : 1 mg/ml		1974
		Dexamethasone sodium phosphate : 4 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Dexamethasone sodium phosphate : 4 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Dexamethasone sodium phosphate : 0.08 mg/ml Netilmicin sulfate : 3 mg/ml		1200
		Dexamethasone sodium phosphate : 0.08 mg/ml Netilmicin sulfate : 3 mg/ml		1200
		Dexamethasone sodium phosphate : 0.2 & 0.4 mg/ml Ondansetron hydrochloride : 0.1 >> 0.64 mg/ml		30
		Dexamethasone sodium phosphate : 0.16 & 0.4 mg/ml Ondansetron hydrochloride : 0.16 mg/ml		2841
		Dexamethasone sodium phosphate : 0,28 & 0,34 mg/ml Ondansetron hydrochloride : 0,14 & 0,45 mg/ml		25
		Dexamethasone sodium phosphate : 0,22 >> 0,43 mg/ml Ondansetron hydrochloride : 0,14 >> 0,76 mg/ml		23
		Dexamethasone sodium phosphate : 0.1 mg/ml Ondansetron hydrochloride : 0.08 mg/ml		3925
		Dexamethasone sodium phosphate : 0,02 >> 0,4 mg/ml Ondansetron hydrochloride : 0,048 & 0,16 mg/ml		992
		Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml Ondansetron hydrochloride : 0.08 mg/ml		3981
		Dexamethasone sodium phosphate : 1 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml Ondansetron hydrochloride : 0.08 mg/ml		3981
		Dexamethasone sodium phosphate : 0.2 & 0.4 mg/ml Ondansetron hydrochloride : 0.1 >> 0.64 mg/ml		30
		Dexamethasone sodium phosphate : 0,1 mg/ml Ondansetron hydrochloride : 0,08 mg/ml		3174
		Dexamethasone sodium phosphate : 0,28 & 0,34 mg/ml Ondansetron hydrochloride : 0,14 & 0,45 mg/ml		25
		Dexamethasone sodium phosphate : 0,22 >> 0,43 mg/ml Ondansetron hydrochloride : 0,14 >> 0,76 mg/ml		23
		Dexamethasone sodium phosphate : 0,02 >> 0,4 mg/ml Ondansetron hydrochloride : 0,048 & 0,16 mg/ml		992
		Dexamethasone sodium phosphate Oxaliplatin		2239
		Dexamethasone sodium phosphate : 1 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Dexamethasone sodium phosphate : 1.2 & 2 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
		Dexamethasone sodium phosphate : 1.2 & 2 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
		Dexamethasone sodium phosphate : 1 & 1.3 mg/ml Oxycodone hydrochloride : 1 & 6.7 mg/ml		2125
		Dexamethasone sodium phosphate : 1 & 1.3 mg/ml Oxycodone hydrochloride : 1 & 6.7 mg/ml		2125

	✓	Dexamethasone sodium phosphate : 1 mg/ml Paclitaxel : 1.2 mg/ml	◆	85
	✓	Dexamethasone sodium phosphate Paclitaxel albumin : 5 mg/ml	▲	4310
	✓	Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml Palonosetron hydrochloride : 2.5 µg/ml	◆	3981
	✓	Dexamethasone sodium phosphate : 0,2 >> 0,4 mg/ml Palonosetron hydrochloride : 5 & 25 µg/ml	▲	1932
	✓	Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml Palonosetron hydrochloride : 2.5 µg/ml	▲	3981
	✓	Dexamethasone sodium phosphate : 0,2 >> 0,4 mg/ml Palonosetron hydrochloride : 5 & 25 µg/ml	◆	1932
		Dexamethasone sodium phosphate Pantoprazole sodium		2090
	✓	Dexamethasone sodium phosphate : 4 mg/ml Paracetamol : 10 mg/ml	∅	3571
	✓	Dexamethasone sodium phosphate : 4 mg/ml Paracetamol : 10 mg/ml		4742
	✓	Dexamethasone sodium phosphate : 1 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953
	✓	Dexamethasone sodium phosphate : 0.2 mg/ml Pethidine hydrochloride : 10 mg/ml	◆	62
	✓	Dexamethasone sodium phosphate : 1 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	◆	81
	✓	Dexamethasone sodium phosphate : 1 mg/ml Plazomicin sulfate : 24 mg/ml	▲	4145
	✓	Dexamethasone sodium phosphate : 4 mg/ml Potassium chloride : 40 mEq/l	▲	730
	✓	Dexamethasone sodium phosphate : 4 mg/ml Potassium chloride : 40 mEq/l	RL	730
	✓	Dexamethasone sodium phosphate : 4 mg/ml Potassium chloride : 40 mEq/l	◆	730
24		Dexamethasone sodium phosphate : 4 mg/ml Propofol		660
	✓	Dexamethasone sodium phosphate : 1 mg/ml Propofol : 10 mg/ml	∅	300
	✓	Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml Ramosetron hydrochloride : 3 µg/ml	◆	3981
	✓	Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml Ramosetron hydrochloride : 3 µg/ml	▲	3981
?		Dexamethasone sodium phosphate Rocuronium bromide		3564
	✓	Dexamethasone sodium phosphate : 0.09 & 0.18 mg/ml Rolapitant : 1.7 mg/ml	∅	3927
	✓	Dexamethasone sodium phosphate : 4 mg/ml Salbutamol sulfate : 1 mg/ml	∅	3216
	✓	Dexamethasone sodium phosphate : 1 mg/ml Sargramostim : 10 µg/ml	▲	335
	✓	Dexamethasone sodium phosphate : 0.2 >> 0.4 mg/ml Scopolamine N-butyl bromide : 3-7 mg/ml	◆	4404
	✓	Dexamethasone sodium phosphate : 0.2 >> 0.4 mg/ml Scopolamine N-butyl bromide : 3-7 mg/ml	▲	4404

		Dexamethasone sodium phosphate : 0.44 & 1.33 mg/ml Scopolamine N-butyl bromide : 1.68 & 5 mg/ml	▲	1971
		Dexamethasone sodium phosphate : 1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml	▲	4801
		Dexamethasone sodium phosphate : 4 mg/ml Tacrolimus : 1000 µg/ml	▲	479
		Dexamethasone sodium phosphate : 1 mg/ml Tedizolid phosphate : 0.8 mg/ml	▲	3827
		Dexamethasone sodium phosphate : 1 mg/ml Telavancin hydrochloride : 7.5 mg/ml	▲	3254
		Dexamethasone sodium phosphate : 1 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Dexamethasone sodium phosphate : 1 mg/ml Telavancin hydrochloride : 7.5 mg/ml	◆	3254
		Dexamethasone sodium phosphate : 1 mg/ml Teniposide : 0.1 mg/ml	◆	905
		Dexamethasone sodium phosphate : 0.08 mg/ml Theophylline : 4 mg/ml	∅	317
		Dexamethasone sodium phosphate : 4 mg/ml Topotecan : 0.056 mg/ml	▲	1026
		Dexamethasone sodium phosphate : 4 mg/ml Topotecan : 0.056 mg/ml	◆	1026
		Dexamethasone sodium phosphate : 0.64 mg/ml Valproic acid : 2 & 20 mg/ml	◆	4428
		Dexamethasone sodium phosphate	▲	3668
		Dexamethasone sodium phosphate : 4 mg/ml Thiopental sodium : 25 mg/ml	▲	3767
		Dexamethasone sodium phosphate : 1 mg/ml Thiotepa : 1 mg/ml	◆	249
		Dexamethasone sodium phosphate : 0.33>>3.33 mg/ml Tramadol hydrochloride : 8.33>>33.33 mg/ml	▲	2211
		Dexamethasone sodium phosphate : 0.44 & 1.33 mg/ml Tramadol hydrochloride : 11.18 & 33.3 mg/ml	▲	1971
		Dexamethasone sodium phosphate : 0.64 mg/ml Valproic acid : 2 & 20 mg/ml	▲	4428
		Dexamethasone sodium phosphate Vancomycin hydrochloride		3668
		Dexamethasone sodium phosphate Vancomycin hydrochloride		3588
		Dexamethasone sodium phosphate : 0.04 mg/ml Verapamil hydrochloride : 0.08 mg/ml	▲	1057
		Dexamethasone sodium phosphate : 0.04 mg/ml Verapamil hydrochloride : 0.08 mg/ml	◆	1057
		Dexamethasone sodium phosphate : 1 mg/ml Vinorelbine tartrate : 1 mg/ml	▲	84
		Dexamethasone sodium phosphate : 0.16 mg/ml Zidovudine : 4 mg/ml	◆	337

Τρόπος χορήγησης

Βιβλιογραφία

	τύπος	δημοσίευση
3	εφημερίδα	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
23	εφημερίδα	Evrard B, Ceccato A, Gaspard O, Delattre L, Delporte JP. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride and in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 1065-1068.
25	εφημερίδα	McGuire TR, Narducci WA, Fox JL. Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1410-1414.
27	εφημερίδα	Chin A, Moon YSK, Chung KC, Gill MA. Stability of granisetron hydrochloride with dexamethasone sodium phosphate for 14 days. Am J Health-Syst Pharm 1996 ; 53: 1174-1176.
28	εφημερίδα	Lau DWC, Law S, Walker SE, Iazzetta J. Dexamethasone phosphate stability and contamination of solutions stored in syringes. PDA J Pharm Sci Technol 1996 ; 50: 261-267.
29	εφημερίδα	Pinguet F, Rouanet P, Martel P, Fabbro M, Salabert D, Astre C. Compatibility and stability of granisetron, dexamethasone, and methylprednisolone in injectable solutions. J Pharm Sci 1995 ; 84: 267-268.
30	εφημερίδα	Hagan RL, Mallett MS, Fox JL. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days. Am J Health-Syst Pharm 1996 ; 53: 1431-1435.
57	εφημερίδα	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
62	εφημερίδα	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
63	εφημερίδα	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	εφημερίδα	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	εφημερίδα	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.

84	εφημερίδα	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	εφημερίδα	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	εφημερίδα	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	εφημερίδα	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
132	εφημερίδα	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
150	εφημερίδα	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
169	εφημερίδα	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	εφημερίδα	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
186	εφημερίδα	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
215	εφημερίδα	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	εφημερίδα	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	εφημερίδα	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
253	εφημερίδα	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
266	εφημερίδα	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
280	εφημερίδα	Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
288	εφημερίδα	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.

300	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	εφημερίδα	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
316	εφημερίδα	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317	εφημερίδα	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	εφημερίδα	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	εφημερίδα	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	εφημερίδα	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	εφημερίδα	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
389	εφημερίδα	Walker SE, DeAngelis C, Iazzetta J, Eppel JG. Compatibility of dexamethasone sodium phosphate with hydromorphone hydrochloride or diphenhydramine hydrochloride. Am J Hosp Pharm 1991 ; 48: 2161-2166.
397	εφημερίδα	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
479	εφημερίδα	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	εφημερίδα	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	εφημερίδα	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	εφημερίδα	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
546	εφημερίδα	Lugo RA, Nahata MC. Stability of diluted dexamethasone sodium phosphate injection at two temperatures. Ann Pharmacotherapy 1994 ; 28: 1018-1019.

660	εφημερίδα	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
730	εφημερίδα	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
905	εφημερίδα	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	εφημερίδα	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
992	εφημερίδα	Beijnen JH, Koks CHW. Visual compatibility of ondansetron and dexamethasone. Ann Pharmacotherapy 1991 ; 25: 869.
1026	εφημερίδα	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1057	εφημερίδα	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	εφημερίδα	Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1200	εφημερίδα	Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742.
1201	εφημερίδα	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1232	εφημερίδα	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1259	εφημερίδα	Jhunjhunwala VP, Bhalla HL. Compatibility of aminophylline with hydrocortisone sodium succinate or dexamethasone sodium phosphate in 5% dextrose injection. Am J Hosp Pharm 1981 ; 38: 900-901.
1410	εφημερίδα	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	εφημερίδα	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	εφημερίδα	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	εφημερίδα	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.

1633	εφημερίδα	Walker SE, Law S. Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions. Can J Hosp Pharm 2002 ; 55: 27-38.
1637	εφημερίδα	Wong AH, Law S, Walker SE, Bowles SK. Concentration-dependant compatibility and stability of dexamethasone and midazolam. Can J Hosp Pharm 2000 ; 53: 24-31.
1662	εφημερίδα	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1701	εφημερίδα	Gupta VD. Chemical stability of dexamethasone sodium phosphate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes. Int J Pharm Compound 2002 ; 6: 395-397.
1712	εφημερίδα	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	εφημερίδα	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	εφημερίδα	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	εφημερίδα	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1866	εφημερίδα	Vermeire A, Remon JP. Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone. Int J Pharm 1998 ; 174: 157-177.
1901	εφημερίδα	Good PD, Schneider JJ, Ravenscroft PJ. The compatibility and stability of midazolam and dexamethasone in infusion solutions. J Pain Symptom Manage 2004 ; 27, 5: 471-475.
1925	εφημερίδα	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1932	εφημερίδα	Trissel LA, Zhang Y. Compatibility and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. Int J Pharm Compound 2004 ; 8,5: 398-403.
1953	εφημερίδα	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1971	εφημερίδα	Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2001
1974	εφημερίδα	Chandler SW, Trissel LA, Weinstein SM Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.

1982	εφημερίδα	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2022	εφημερίδα	Watson DG, Lin M, Morton A, Cable CG, McArthur DA. Compatibility and stability of dexamethasone sodium phosphate and ketamine hydrochloride subcutaneous infusions in polypropylene syringes. J Pain Symptom Manage 2005 ; 30: 80-86.
2087	εφημερίδα	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	εφημερίδα	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	εφημερίδα	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2125	εφημερίδα	Gardiner PR. Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003 ; 10: 354-361.
2132	εφημερίδα	Anderson Collin R, Halford Zachery, MacKay Mark. Stability of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone Sodium Phosphate in 0.9% Sodium Chloride Stored in Polypropylene Syringes. Int J Pharm Compound 2015 ; 19, 4 : 344-347.
2205	εφημερίδα	Negro S, Rendon AL, Azuara ML, S?nchez Y, Fern?ndez-Carballido A, Barcia E. Compatibility and stability of furosemide and dexamethasone combined in infusion solutions. Arzneimittel Forschung 2006 ; 56, 10: 714-720.
2211	εφημερίδα	Negro S, Salama A, S?nchez Y, AzuaraM.L, Barcia B. Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients. J Clin Pharm Ther 2007 ; 32: 441-444.
2239	εφημερίδα	Wang C, Zhang X, Liu HY. Determination of the stability of oxaliplatin for injection by dual wavelength spectrophotometry. Chinese J New Drugs 2005 ; 14, 2: 189-191.
2262	εφημερίδα	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	εφημερίδα	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2335	εφημερίδα	Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2841	εφημερίδα	Gonzalves Navaro M, Carril Aviles M, Borras Almenar C, Romero Crespo I, Jimenez Torres NV. Estudio de estabilidad de la mezcla ondansetron-dexametasona en cloruro sodico 0,9%. Atencion Pharmaceutica 2009 ; 11, 3: 161-166.
2900	εφημερίδα	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3012	εφημερίδα	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.

3174	εφημερίδα	Rolin C, Hecq JD, Vanbeckbergen DF, Jamart J, Galanti LM. Stability of Ondansetron and Dexamethasone Infusion upon Refrigeration. Ann Pharmacotherapy 2011 ; 45: 130-131.
3184	Εργαστήριο	 Hyaluronidase (Hyalase®) - Summary of Product characteristics.
3216	εφημερίδα	Legris M.E, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	εφημερίδα	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	εφημερίδα	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	εφημερίδα	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3459	εφημερίδα	Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3545	Εργαστήριο	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3564	Εργαστήριο	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3571	εφημερίδα	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3577	Εργαστήριο	Daunorubicine (Daunoxome®) - Résumé des caractéristiques du produit Galen Limited
3588	Εργαστήριο	Vancomycine (Vancocin®) - Résumé des caractéristiques du produit Sandoz 2011
3604	Εργαστήριο	Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3644	Εργαστήριο	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3646	Εργαστήριο	Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit Sanofi Aventis France 2013
3668	Εργαστήριο	Dexamethasone - Summary of Product Characteristics Hospira 2015
3766	εφημερίδα	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	εφημερίδα	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3779	εφημερίδα	Kintzel P.E, Zhao T, Wen B, Sun D. Stability of i.v. admixture containing metoclopramide, diphenhydramine hydrochloride, and dexamethasone sodium phosphate in 0.9% sodium chloride injection Am J Health-Syst Pharm 2014 ; 71:2061-2065

3824	εφημερίδα	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	αφίσα	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	αφίσα	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	αφίσα	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3838	Εργαστήριο	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3925	εφημερίδα	Simar J, Godet M, Hecq J.-D, Closset M, Gillet P, Langhendries C, Bihin B, Jamart J, Galanti L. Long-term stability of dexamethasone and alizapride or ondansetron in sodium chloride 0.9% polyolefin bag at 5±3 C. Ann Pharm Fr 2016 ; 75, 1 : 30-39.
3927	εφημερίδα	Wu G,Yeung S,Chen F. Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate. Int J Pharm Compound 2017 ; 21, 1 : 66-75.
3964	εφημερίδα	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3967	εφημερίδα	Staven V, Herra I, Wang S, Grönlie I,Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
3976	εφημερίδα	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3981	εφημερίδα	He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D. Compatibility of dexamethasone sodium phosphate with 5-HT3 receptor antagonists in infusion solutions: a comprehensive study EJHP 2017 ;24:162?166
4055	εφημερίδα	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4062	εφημερίδα	Wu George, Powers Dan, Yeung S, Chen F, Neelon K. Compatibility and stability of VARUBI (Rolapitant) injectable emulsion admixed with intravenous palonosetron hydrochloride injection and dexamethasone sodium phosphate injection. Int J Pharm Compound 2018 ;22,1:76-85
4145	εφημερίδα	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4154	Εργαστήριο	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4301	εφημερίδα	Fang B-X, Chen F-C, Zhu D, Guo J, Wang L-H. Stability of azasetron-dexamethasone mixture for chemotherapyinduced nausea and vomiting administration. Oncotarget 2017 ;8, 63: 106249-106257.

4310	εφημερίδα	Mizuta N, Nakagawa T, Yamamoto K, Nishioka T, Kume M, Makimoto H, Yano I, Minami H, Hiral M. Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs. Kaohsiung J Med Sci 2017 ; 63, 1: E9-E16.
4319	εφημερίδα	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	εφημερίδα	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4404	αφίσα	Müller U, Haller F, Wiedemeier P, Steuer C. Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. JFSPH 2019 2019
4428	εφημερίδα	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4433	εφημερίδα	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4528	εφημερίδα	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4602	εφημερίδα	Buga I, Uzoma J.I, Reindel K, Rashid K, Diep T, McCartan P, Zhao F. Physical and Chemical Stability of Dexamethasone Sodium Phosphate in Intravenous Admixtures Used to Prevent Chemotherapy-Induced Nausea and Vomiting. Hosp Pharm 2021 ; 56, 4: 215-220.
4603	εφημερίδα	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	εφημερίδα	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4776	εφημερίδα	Tomczak S, Chmielewski, M, Szkudlarek J, Jeliinska A. Antiemetic Drugs Compatibility Evaluation with Paediatric Parenteral Nutrition Admixtures. Pharmaceutics 2023 ; 15: 2143.
4801	εφημερίδα	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4964	Εργαστήριο	GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - Résumé des caractéristiques du produit. B BRAUN MELSUNGEN AG 2019
4982	Εργαστήριο	Diamorphine Hydrochloride 100mg for Injection - Summary of Product Characteristics Updated 06-May-2020. Wockhardt UK Ltd 2020
5046	Εργαστήριο	Metaraminol 10 mg/ml Solution for Injection or Infusion - Package leaflet: Information for the user. Global Harvest Pharmaceuticals 2020
5073	Εργαστήριο	Palladone 10 mg/ml solution for injection or infusion - Summary of Product Characteristics Updated 28-Apr-2025. Napp Pharmaceuticals Limited 2025

Stabilis

Dexamethasone sodium phosphate



Σταθερότητα και συμβατότητα των φαρμάκων

	20 & 40 mg ®=? (Sabex)		OraPlus® / OraSweet® (1:1) >> 40 ml	25 °C		91			2961
	20 & 40 mg ®=? (Sabex)		OraPlus® / OraSweet® (1:1) >> 40 ml	4 °C		91			2961

Βιβλιογραφία

	τύπος	δημοσίευση
2961	εφημερίδα	Wen-Lin Chow J, Decarie D, Dumont RJ. Stability of dexamethasone in extemporaneously prepared oral suspensions. Can J Hosp Pharm 2001 ; 54: 96-101.

Λεξικό

	Αντιφλεγμονώδες		Ενέσιμο
	Εμπορική ονομασία		Σταθερότητα διαλυμάτων
	Υποδοχέας		Μόριο Mório
	Συγκέντρωση		Θερμοκρασία
	Αποθήκευση		Διάρκεια σταθερότητας
	βιοϊσοδύναμα		αντικρουόμενα δεδομένα
	Βιβλιογραφία		Ύαλος
	Ενέσιμο ύδωρ + αντιβακτηριακό		Φως
	Ημέρα	PVC	Πολυβινυλοχλωρίδιο
	Χλωριούχο νάτριο 0,9%	?	Απροσδιόριστο
	Γλυκόζη 5%		σύριγγα πολυπροπυλένιο
?	Απροσδιόριστο		NaCl 0,9% + αντιβακτηριακό
	Προστατεύετε από το φως		Σταθερότητα σε μίγματα
	Διαλυτικό		Συστατικό
	Ώρα	RL	Γαλακτικό διάλυμα Ringer
0.45	Χλωριούχο νάτριο 0,45%	Ø	Ουδέν
PE	Πολυαιθυλένιο	PP	Πολυπροπυλένιο
POF	Πολυολεφίνη	CZ®	Cristal Zenith®
	Συμβατότητες		Σύμφωνος
	Απροσδιόριστη ασυμβατότητα		Ασύμβατες
	Άμεση βροχόπτωση	1	Καταβύθιση μετά από 1 ώρα
	Ενέσιμο ύδωρ		Άμεση θολότητα
	Παρεντερική διατροφή (με λιπίδια)		Παρεντερική θρέψη (ελεύθερο λιπιδίων)
	Ειδικά διαλύτη	1	Мътност за един час
ΔpH >±1	Τροποποίηση pH> 1 μονάδα pH	4	Αλλαγή χρώματος μετά από 4 ώρες
	Χημική αστάθεια	24	Αστάθεια του γαλακτώματος μετά από 24 ώρες
	Τρόπος χορήγησης		Ενδοφλέβια
	Ενδοφλέβια έκχυση		Ενδομυϊκή
	Υποδόριος		Ενδοαρθρωτική
	Βιβλιογραφία		Πόσιμο διάλυμα

	Σταθερότητα και συμβατότητα των φαρμ		Origine
	Έκδοχο		Πλαστικό μπουκάλι
	Φιαλίδιο φαρμάκου για ένεση		Λεξικό